Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub Saharan Africa and South East Asia

In this study, we manufactured HCV replicons which express the NS5A protein from the unusual HCV subtypes 1l, 3b, 3g, 4r, 6u, 6v. We then tested the effect of the NS5A inhibitors daclatasvir, elbasvir, ledipasvir, pibrentasvir and velpa tasvir on blocking replication on these replicons. We show that these replicons are resistance at some level to all NS5A inhibitors other than pibrentasvir.

Source: Journal of Hepatology - May 25, 2020 Category: Gastroenterology Authors: Dung Nguyen, David Smith, Alun Vaughan-Jackson, Andrea Magri, Eleanor Barnes, Peter Simmonds, STOP-HCV Consortium Source Type: research